- Home
- GHI vs NMRA Comparison
GHI vs NMRA Comparison
Compare GHI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- NMRA
- Stock Information
- Founded
- GHI 1998
- NMRA 2019
- Country
- GHI United States
- NMRA United States
- Employees
- GHI N/A
- NMRA N/A
- Industry
- GHI Finance: Consumer Services
- NMRA
- Sector
- GHI Finance
- NMRA
- Exchange
- GHI Nasdaq
- NMRA Nasdaq
- Market Cap
- GHI 269.5M
- NMRA 121.0M
- IPO Year
- GHI N/A
- NMRA 2023
- Fundamental
- Price
- GHI $11.48
- NMRA $0.84
- Analyst Decision
- GHI Strong Buy
- NMRA Buy
- Analyst Count
- GHI 4
- NMRA 8
- Target Price
- GHI $16.00
- NMRA $9.29
- AVG Volume (30 Days)
- GHI 49.2K
- NMRA 1.4M
- Earning Date
- GHI 08-06-2025
- NMRA 08-05-2025
- Dividend Yield
- GHI 12.89%
- NMRA N/A
- EPS Growth
- GHI N/A
- NMRA N/A
- EPS
- GHI 0.45
- NMRA N/A
- Revenue
- GHI $34,065,322.00
- NMRA N/A
- Revenue This Year
- GHI $228.92
- NMRA N/A
- Revenue Next Year
- GHI $4.27
- NMRA N/A
- P/E Ratio
- GHI $25.65
- NMRA N/A
- Revenue Growth
- GHI N/A
- NMRA N/A
- 52 Week Low
- GHI $10.12
- NMRA $0.61
- 52 Week High
- GHI $15.27
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- GHI 45.71
- NMRA 52.19
- Support Level
- GHI $11.10
- NMRA $0.72
- Resistance Level
- GHI $11.67
- NMRA $0.85
- Average True Range (ATR)
- GHI 0.36
- NMRA 0.07
- MACD
- GHI -0.07
- NMRA -0.01
- Stochastic Oscillator
- GHI 40.88
- NMRA 62.35
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.